Tenax Therapeutics, Inc.
NASDAQ:TENXBiotechnology
+$0.10 today
- Market cap
- $50.66M
- Beta
- 0.97
- P/E (TTM)
- -9.4
- EPS (TTM)
- -$1.28
Volume 0.70M
Average 0.62M
TENX Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Tenax Therapeutics, Inc.NASDAQ: TENX
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity rises 4.9% from a year ago
Total equity stood at $114.69M at the end of Q1 FY2026, up 4.9% from a year earlier and up 18.2% from the prior quarter. Over 3 fiscal years it compounded at +302.1% a year.
Context
- Total equity amounted to 93.1% of total assets at the end of Q1 FY2026, down 4.4 pp from a year earlier.
- Total equity increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +4.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 97.07M USD
- Year-over-year change
- +5.5%
- 4-year CAGR
- +118.7%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 97.07M | +5.5% |
| FY2024 | 2024-12-31 | 91.99M | +1036.0% |
| FY2023 | 2023-12-31 | 8.1M | +442.5% |
| FY2022 | 2022-12-31 | 1.49M | -64.8% |
| FY2021 | 2021-12-31 | 4.24M | — |
Total Equity vs competitors
How TENX compares with its peers on the latest reported figures
- TENX's Mar 2026 total equity of $114.69M is the 2nd highest of the 7 companies compared; the peer median is $64.04M.
- Its year-over-year change of +4.9% is the 5th highest of 7, against a peer median of +99.0%.
- Total equity amounts to 93.1% of total assets for TENX, versus a peer median of 81.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $214.79M | +1687.5% | +69.6% | 90.2% | |
| Mar 2026 | $114.69M | +4.9% | +302.1% | 93.1% | |
| Mar 2026 | $86.38M | -36.8% | — | 61.3% | |
| Mar 2026 | $81.76M | +11.5% | -17.8% | 93.4% | |
| Mar 2026 | $46.31M | +1253.8% | — | 72.7% | |
| Mar 2026 | $16.06M | +186.4% | -14.8% | 41.4% | |
| Jun 2026 | -$201.56B | -627630.4% | — | 212.0% | |
| Peer median (excluding TENX) | $64.04M | +99.0% | -14.8% | 81.4% | |
Competitors are the stored peer set for TENX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Tenax Therapeutics, Inc.
NASDAQ:TENX
Intrinsic Alpha fair value
Locked
Current Price
$1.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.